Abstract
In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4-8 |
| Number of pages | 5 |
| Journal | Bioconjugate chemistry |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 16 2013 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Biomedical Engineering
- Pharmacology
- Pharmaceutical Science
- Organic Chemistry
Fingerprint
Dive into the research topics of 'H-Gemcitabine: A new gemcitabine prodrug for treating cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS